BGB-A445 / BeiGene 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BGB-A445 / BeiGene
BGB-A317-290-LTE1, NCT04164199 / 2019-002554-23: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Enrolling by invitation
3
300
Europe, Japan, US, RoW
Tislelizumab, BGB-A317, Pamiparib, BGB-290, Temozolomide, Sitravatinib, Ociperlimab, BGB-A1217, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, ZW25, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007
BeiGene
Advanced Malignancies
12/26
12/26
BGB-A317-A445-101, NCT04215978: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Active, not recruiting
2
342
US, RoW
BGB-A445, tislelizumab, BGB-A317
BeiGene
Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Nasopharyngeal Carcinoma (NPC)
11/24
11/24
BGB-LC-201, NCT05635708: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Recruiting
2
400
Europe, Canada, US, RoW
Tislelizumab, BGB-A445, LBL-007, Carboplatin, Cisplatin, pemetrexed, Paclitaxel, Nab paclitaxel, BGB-15025
BeiGene
Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
07/25
07/25
NCT06029127: A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

Active, not recruiting
2
35
RoW
BGB-A445, Docetaxel, Ramucirumab, BGB-15025
BeiGene
Non-Small Cell Lung Cancer
12/24
12/24
NCT05661955: A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

Recruiting
1/2
202
RoW
BGB-A445, Tislelizumab
BeiGene
Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma
04/26
09/26

Download Options